fda022-bb05
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 13, 2024 (NCT06413615)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Payload
- BB05
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06413615 | Phase 2 | May 13, 2024 | Fudan University, Shanghai Zhangjiang Biotechnology Limited Company |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Shanghai Zhangjiang Biotechnology Limited Company | For profit | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1